However, no relevant clinical trials have been conducted until now, thus early stage clinical studies are needed to understand the feasibility and efficacy of these dual PI3K/mTOR inhibitors in combination with radiotherapy in cancer patients. This evidence concerns the gene PIK3CB and cancer.